The following is a summary of “Efficacy and Safety of Upadacitinib for Perianal Fistulizing Crohn’s Disease: A Post Hoc Analysis of 3 Phase 3 Trials,” published in the May 2025 issue of Clinical Gastroenterology and Hepatology by Colombel et al.
The post Clinical Benefits of Upadacitinib for Fistulizing Crohn’s Disease first appeared on Physician’s Weekly.
